Lymphangioleiomyomatosis Evidence Based Practice (LAM)

Tuesday, April 24, 2018, 12:00 AM - Friday, April 24, 2020, 11:59 PM

AMA PRA Category 1 Credits™ (1.00 hours), ABIM MOC Part 2 (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

In this activity, pulmonologists with expertise in rare lung diseases discuss the current evidence-based practices for diagnosis and treatment of lymphangioleiomyomatosis (LAM).

For more information about Lymphangioleiomyomatosis, visit The LAM Foundation.

Free Online Certified CME/MOC

In order to complete tests, evaluations, and receive educational credits, you must sign-in.

1. If you were a user in our previous online CME portal and this is your first time signing in to our NEW CME portal, please click ‘Forgot Your Password,’ enter your email address and click ‘Reset Password.’ An email will be delivered with a link to set up your password. Please do not create a new account. If you need to confirm the email on your account, please contact the CME Office.
2. If you are a physician, and would like to receive ABIM MOC credit for participating in this activity, you will need to provide your ABIM number. Please provide this information under your user profile account. This information will be submitted to the Accreditation Council for Continuing Medical Education (ACCME) for the purpose of granting MOC credit only.

Requirements for Successful Completion

In order to receive credit, participants must complete the pretest, view the activity, and complete the post-test, and evaluation form; You must obtain a passing score of 70% on the post-test. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

1. Summarize the role of high-resolution chest CT scan, serum VEGF-D testing, and transbronchial lung biopsy in the diagnosis of LAM, and follow an algorithmic pathway that establishes the diagnosis of LAM in the least invasive manner possible.
2. Interpret the role of doxycycline and hormonal therapy in the treatment of LAM.
3. Identify LAM patients who should be treated with sirolimus, and determine the role of sirolimus in the treatment of chylous effusions among patients with LAM.
4. Recognize the benefits of early pleurodesis to avoid recurrence of pneumothorax.
5. Recognize that pleurodesis is not a contraindication for future lung transplantation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Rare Lung Disease Consortium. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Association for Respiratory Care (AARC)
This Non-traditional program has been approved for 1.00 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care, 9425 N. MacArthur Blvd. Suite 100 Irving TX 75063
Course # 151114000.

FACULTY & DISCLOSURE / CONFLICT OF INTEREST POLICY

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Medical Directors & Program Planner

Francis McCormack, MD, Medical Director
Nishant Gupta, MD, FCCP, Medical Director
Laura Bowers, PharmD, MS, Educational Program Planner

University of Cincinnati Continuing Medical Education Office

Deborah Cole, BS, Program Coordinator
Heather Muskopf, Program Manager
Rick E. Ricer, MD, Professor Emeritus, Physician Reviewer
Susan P. Tyler, MEd, CMP,  CHCP, Director, Continuing Medical Education

Disclosure of Unlabeled Use 

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. 

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. 

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of  University of Cincinnati, Rare Lung Disease Consortium or any of its supporters.

To view faculty disclosures, visit the faculty tab.

This activity is supported by an independent educational grant from The UNC Eshelman Institute for Innovation, the LAM Foundation, and the Rare Lung Disease Consortium.